StockData
Sight Sciences, Inc. logo

Sight Sciences, Inc. (SGHT) company profile

SGHTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30164% above fair value
$10.77+0.28 (+2.67%)

Close on Nov 18, 2026Market cap $593.30MP/E –Yield –

About Sight Sciences

Surgical & Medical Instruments & Apparatus, SIC 3841

Sight Sciences, Inc. is an ophthalmic medical device company that develops surgical and therapeutic technologies for eye conditions, primarily glaucoma and dry eye disease. The company operates in two segments: Interventional Glaucoma and Interventional Dry Eye. In the Interventional Glaucoma segment, it offers the OMNI Surgical System to reduce intraocular pressure in adults with primary open-angle glaucoma, and the SION Surgical Instrument to excise trabecular meshwork tissue. In the Interventional Dry Eye segment, it offers the TearCare system, which applies localized heat to clear meibomian gland obstructions. Its customers are eyecare professionals, including ophthalmic surgeons, ophthalmologists, and optometrists.

The company maintains direct commercial operations in the United States, the United Kingdom, and Germany, and sells products in other European countries through distributors. Within the United States, it markets its products through dedicated sales forces. Sight Sciences is headquartered in Menlo Park, California.

Summary of the business section of Sight Sciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Sight Sciences, Inc.
Headquarters
Menlo Park, CA
Address
4040 Campbell Ave,, Suite 100 94025
Phone
(415) 889-0550
Employees
186, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
DELOITTE & TOUCHE LLP, San Jose, California

Stock & identifiers

Ticker
SGHT
Exchange
Nasdaq
IPO date
Jul 15, 2021
Shares outstanding
55M, Jul 31, 2026
Public float
$153.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1531177
CUSIP
82657M105
ISIN
US82657M1053
FIGI
BBG006BZHZC7
Share class FIGI
BBG006BZHZD6
EIN
80-0625749

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Paul BadawiPresident and CEO, Director6,092,819
David BadawiChief Technology Officer, Director1,975,075
Brenton TaylorEVP, Operations & R&D261,990
Alison BauerleinChief Operating Officer639,449
James RodbergChief Financial Officer216,829
Kashif RashidChief Legal Officer181,818
Jeremy B. HaydenChief Legal Officer357,037
Manohar K. RahejaEVP, Research & Development167,767
Matthew LinkChief Commercial Officer832,293
Staffan EncrantzDirector6,521,203
Gerhard F. BurbachDirector123,207
Catherine MazzaccoDirector106,768
Donald ZurbayDirector193,613
Tamara FountainDirector109,650
Brenda Jane Larsen-BeckerDirector79,040
Erica J. RogersDirector175,352

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Paul Badawi
President and Chief Executive Officer
$659.00K$1.00M$334.61K$12.00K$2.01M-34%
Alison Bauerlein
Chief Operating Officer
$474.90K$950.00K$196.50K$5.25K$1.63M-27%
Jeremy Hayden
Chief Legal Officer
$433.00K$390.00K$146.57K$4.68K$974.25K-34%
Matthew Link
Chief Commercial Officer
$288.13K$480.00K–$448.79K$1.22M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 15, 2021
Offer price
$24.00
Securities offered
10,000,000
Gross proceeds
$240.00M
Exchange
Nasdaq
First trading day
Jul 15, 2021
First-day close
$33.50+39.6%
Lock-up ends (est.)
Jan 11, 2022

“The initial public offering price of our common stock is $24 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 186 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?